(1S,2R)-ritodrine : A 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol that has (1S,2R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 688570 |
| CHEMBL ID | 489553 |
| CHEBI ID | 156577 |
| SCHEMBL ID | 12959065 |
| MeSH ID | M0019137 |
| Synonym |
|---|
| AB00698529-06 |
| 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)benzenemethanol (r*,s*)- |
| benzenemethanol, 4-hydroxy-alpha-(1-((2-(4-hydroxyphenyl)ethyl)amino)ethyl)-, (r*,s*)- |
| benzyl alcohol, p-hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)-, erythro- |
| 2-(4-hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol |
| einecs 247-879-9 |
| erythro-p-hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol |
| brn 2388728 |
| LOPAC0_001041 |
| 26652-09-5 |
| NCGC00162324-01 |
| NCGC00162324-02 |
| (+)-ritodrine |
| (1s,2r)-ritodrine |
| (1s,2r)-2-(4-hydroxyphenethylamino)-1-(4-hydroxyphenyl)-1-propanol |
| (+)-erythro-1-(p-hydroxyphenyl)-2-[2-(p-hydroxyphenyl)ethylamino]-1-propanol |
| CHEBI:156577 |
| 4-[(1s,2r)-1-hydroxy-2-{[2-(4-hydroxyphenyl)ethyl]amino}propyl]phenol |
| 4-[2-[[(1s,2r)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol |
| CHEMBL489553 |
| rel-ritodrine |
| CCG-205118 |
| i0q6o6740j , |
| ritodrine [usan:inn:ban] |
| unii-i0q6o6740j |
| ritodrine [usan] |
| ritodrine [who-dd] |
| ritodrine [vandf] |
| ritodrine [mi] |
| ritodrine [inn] |
| ritodrinehydrochloride |
| SCHEMBL12959065 |
| AB00698529_07 |
| 4-(2-((1s,2r)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol |
| bdbm50493311 |
| SDCCGSBI-0051011.P002 |
| NCGC00162324-06 |
| HY-B0452A |
| CS-0013783 |
| Class | Description |
|---|---|
| 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol | A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.1158 | 0.0184 | 6.8060 | 14.1254 | AID624148 |
| GLS protein | Homo sapiens (human) | Potency | 3.1623 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 0.0946 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| arylsulfatase A | Homo sapiens (human) | Potency | 10.6910 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0224 | 5.9449 | 22.3872 | AID488983 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | Kd | 0.0005 | 0.0000 | 0.6288 | 8.9130 | AID770362 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| amyloid-beta binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| beta2-adrenergic receptor activity | Beta-2 adrenergic receptor | Homo sapiens (human) |
| protein binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| adenylate cyclase binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| potassium channel regulator activity | Beta-2 adrenergic receptor | Homo sapiens (human) |
| identical protein binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| protein homodimerization activity | Beta-2 adrenergic receptor | Homo sapiens (human) |
| protein-containing complex binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| norepinephrine binding | Beta-2 adrenergic receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Beta-2 adrenergic receptor | Homo sapiens (human) |
| lysosome | Beta-2 adrenergic receptor | Homo sapiens (human) |
| endosome | Beta-2 adrenergic receptor | Homo sapiens (human) |
| early endosome | Beta-2 adrenergic receptor | Homo sapiens (human) |
| Golgi apparatus | Beta-2 adrenergic receptor | Homo sapiens (human) |
| plasma membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| endosome membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| apical plasma membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| clathrin-coated endocytic vesicle membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| neuronal dense core vesicle | Beta-2 adrenergic receptor | Homo sapiens (human) |
| receptor complex | Beta-2 adrenergic receptor | Homo sapiens (human) |
| plasma membrane | Beta-2 adrenergic receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID770363 | Induction of Mitochondrial biogenesis in rabbit RPT cells after 24 hrs by FCCP-OCR assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis. |
| AID770362 | Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM | 2013 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19 | β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (65.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study on Tocolysis in Prevention of Preterm Labour [NCT03298191] | Phase 4 | 300 participants (Anticipated) | Interventional | 2017-10-25 | Recruiting | ||
| Pilot Study: A Dose-Response Finding Study of Ritodrine (Pre-Par®) to Find the Highest Well Tolerated Dose in Young, Healthy, Female Volunteers. To Find the Size-Order of the Hemodynamical Effects of Ritodrine (PrePar®) and Atosiban (Tractocile®) to Deter [NCT00679705] | Phase 1 | 23 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor [NCT02538718] | 34 participants (Actual) | Interventional | 2015-09-22 | Completed | |||
| Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor: Randomized Controlled Trial [NCT00290173] | 0 participants | Interventional | Completed | ||||
| Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor: A Randomized Controlled Trial [NCT03040752] | Phase 4 | 200 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||